During the past decade, Policlinico Tor Vergata conducted 113 clinical trials. In the 10-year time frame, 113 clinical trials started and 51 clinical trials were completed, i.e. on average, 45.1% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 33 clinical trials were completed. i.e. 78.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Policlinico Tor Vergata" #1 sponsor was "Celgene" with 13 trials, followed by "Eli Lilly and Company" with 10 trials sponsored, "Boehringer Ingelheim" with 9 trials sponsored, "Hoffmann-La Roche" with 9 trials sponsored and "University of Rome Tor Vergata" with 9 trials sponsored. Other sponsors include 117 different institutions and companies that sponsored additional 82 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Policlinico Tor Vergata" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator, "Azienda Policlinico Umberto I" with 2 trials as a collaborator, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 2 trials as a collaborator and "University of Rome Tor Vergata" with 2 trials as a collaborator. Other collaborators include 37 different institutions and companies that were collaborators in the rest 47 trials.

According to Clinical.Site data, the most researched conditions in "Policlinico Tor Vergata" are "Ulcerative Colitis" (12 trials), "Myelodysplastic Syndromes" (10 trials), "Crohn Disease" (9 trials), "Leukemia" (6 trials) and "Psoriasis" (6 trials). Many other conditions were trialed in "Policlinico Tor Vergata" in a lesser frequency.

Most popular intervention types in "Policlinico Tor Vergata" are "Drug" (115 trials), "Other" (22 trials), "Device" (13 trials), "Procedure" (10 trials) and "Biological" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Azacitidine" (4 trials), "Dexamethasone" (4 trials), "GED-0301" (4 trials) and "Mirikizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Policlinico Tor Vergata" are 168 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Policlinico Tor Vergata". 1 are not yet recruiting, 27 are recruiting, 19 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 80 completed trials in Policlinico Tor Vergata, 1 suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in Policlinico Tor Vergata, 6 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 74 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 16 trials that are defined as “Not Applicable".

Policlinico Tor Vergata has several departments that took part in Clinical trials: "Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla" - 9 trials, "Fondazione Ptv Policlinico Tor Vergata Di Roma;U.O.S.D. Patologie Renitiche" - 6 trials, "Policlinico Tor Vergata (PTV) Foundation: UOC Department of Diagnostic Imaging and Interventional Radiology" - 2 trials, "UOC Medicina Interna" - 2 trials, "Az. Osp. Uni Ria Policlinico Tor Vergata; Unita Di Ematologia" - 3 trials, "Azienda Ospedaliera Universitaria Policlinico Tor Vergata; Neurologia" - 2 trials, "Fondazione PTV - Policlinico Tor Vergata I U.0.C. Neurologia" - 2 trials, "Policlinico Tor Vergata; Divisione Di Reumatologia" - 2 trials